Effects of quipazine on blood pressure in pithed rats. 1983

Y K Shin, and P Svinareff, and H Schmitt-Jubeau, and H Schmitt

The effects of quipazine on blood pressure in pithed rats and the mechanism of the pressor response were studied. Quipazine and 5 HT produced an abrupt increase in blood pressure. The pressor responses were reduced by phentolamine and phenoxybenzamine. The noradrenaline depletion induced by pretreatment with reserpine significantly reduced the pressor effects of quipazine. Methysergide, at a dose which did not alter pressor responses to noradrenaline, reduced the increase in blood pressure induced by quipazine and 5 HT. These results suggest that quipazine activates 5-hydroxytryptaminergic receptors stimulating the release of noradrenaline. The effect observed in reserpinized rats can be explained by the interconnection of 5-hydroxytryptamine receptors and alpha-adrenoceptors.

UI MeSH Term Description Entries
D008297 Male Males
D008784 Methysergide An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome. Dimethylergometrin,Methylmethylergonovine,Deseril,Desril,Désernil-Sandoz,Methysergide Dimaleate,Methysergide Maleate,Sansert,UML-491,Dimaleate, Methysergide,Désernil Sandoz,Maleate, Methysergide,UML 491,UML491
D011804 Quinolines
D011814 Quipazine A pharmacologic congener of serotonin that contracts smooth muscle and has actions similar to those of tricyclic antidepressants. It has been proposed as an oxytocic. 2-(1-Piperazinyl)quinoline,MA-1291,Quipazine Hydrochloride,Quipazine Maleate,Quipazine Maleate (1:1),MA 1291,MA1291
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D012110 Reserpine An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. Raunervil,Raupasil,Rausedil,Rausedyl,Serpasil,Serpivite,V-Serp,V Serp
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003655 Decerebrate State A condition characterized by abnormal posturing of the limbs that is associated with injury to the brainstem. This may occur as a clinical manifestation or induced experimentally in animals. The extensor reflexes are exaggerated leading to rigid extension of the limbs accompanied by hyperreflexia and opisthotonus. This condition is usually caused by lesions which occur in the region of the brainstem that lies between the red nuclei and the vestibular nuclei. In contrast, decorticate rigidity is characterized by flexion of the elbows and wrists with extension of the legs and feet. The causative lesion for this condition is located above the red nuclei and usually consists of diffuse cerebral damage. (From Adams et al., Principles of Neurology, 6th ed, p358) Decerebrate Posturing,Decorticate Rigidity,Decorticate State,Rigidity, Decerebrate,Rigidity, Decorticate,Decerebrate Posturings,Decerebrate Rigidity,Decerebrate States,Decorticate Rigidities,Decorticate States,Posturing, Decerebrate,Posturings, Decerebrate,Rigidities, Decorticate,State, Decerebrate,States, Decerebrate
D005260 Female Females
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic

Related Publications

Y K Shin, and P Svinareff, and H Schmitt-Jubeau, and H Schmitt
January 1995, Proceedings of the Western Pharmacology Society,
Y K Shin, and P Svinareff, and H Schmitt-Jubeau, and H Schmitt
January 1998, Proceedings of the Western Pharmacology Society,
Y K Shin, and P Svinareff, and H Schmitt-Jubeau, and H Schmitt
February 1983, European journal of pharmacology,
Y K Shin, and P Svinareff, and H Schmitt-Jubeau, and H Schmitt
January 1991, Proceedings of the Western Pharmacology Society,
Y K Shin, and P Svinareff, and H Schmitt-Jubeau, and H Schmitt
January 1986, General pharmacology,
Y K Shin, and P Svinareff, and H Schmitt-Jubeau, and H Schmitt
May 1992, European journal of pharmacology,
Y K Shin, and P Svinareff, and H Schmitt-Jubeau, and H Schmitt
January 1984, European journal of pharmacology,
Y K Shin, and P Svinareff, and H Schmitt-Jubeau, and H Schmitt
November 1989, The Journal of pharmacy and pharmacology,
Y K Shin, and P Svinareff, and H Schmitt-Jubeau, and H Schmitt
September 1979, The American journal of physiology,
Y K Shin, and P Svinareff, and H Schmitt-Jubeau, and H Schmitt
January 1995, Archives of medical research,
Copied contents to your clipboard!